Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Barrett Esophagus

  • Author: Mark H Johnston, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
 
Updated: Jun 22, 2016
 

Practice Essentials

In Barrett esophagus, healthy esophageal epithelium is replaced with metaplastic columnar cells—the result, it is believed, of damage from prolonged exposure of the esophagus to the refluxate of gastroesophageal reflux disease (GERD). The inherent risk of progression from Barrett esophagus to adenocarcinoma of the esophagus has been established.

Signs and symptoms

The classic picture of a patient with Barrett esophagus is a middle-aged (55 yr) white man with a chronic history of gastroesophageal reflux—for example, pyrosis, acid regurgitation, and, occasionally, dysphagia. Some patients, however, deny having any symptoms.

The features of GERD in relation to long-segment Barrett esophagus (LSBE, >3 cm) and short-segment Barrett esophagus (SSBE, < 3 cm) are quite different.

GERD in LSBE

  • Patients with LSBE tend to have a longer duration of reflux symptoms
  • When undergoing 24-hour esophageal pH monitoring, they have severe, combined patterns of reflux (supine and erect) and reduced lower esophageal sphincter (LES) pressures
  • Patients also tend to be less sensitive to direct acid exposure

GERD in SSBE

Patients are more sensitive to acid exposure but have had symptoms for a shorter duration, with normal LES pressures and only upright reflux on 24-hour esophageal pH testing.

See Clinical Presentation for more detail.

Diagnosis

The following techniques are used in the diagnosis and assessment of Barrett esophagus:

  • Esophagogastroduodenoscopy (EGD): The procedure of choice for the diagnosis of Barrett esophagus
  • Biopsy: The diagnosis of Barrett esophagus requires biopsy confirmation of specialized intestinal metaplasia (SIM) in the esophagus
  • Ultrasonography: When high-grade dysplasia or cancer is found on surveillance endoscopy, endoscopic ultrasonography (EUS) is advisable to evaluate for surgical resectability

The Practice Parameters Committee of the American College of Gastroenterology recommends that patients with long-standing GERD symptoms (>5 yr), particularly those aged 50 years or older, have an upper endoscopy to detect or screen for Barrett esophagus.

See Workup for more detail.

Management

Once Barrett esophagus has been identified, patients should undergo periodic surveillance endoscopy to identify histologic markers for increased cancer risk (dysplasia) or cancer that is at an earlier stage and is amenable to therapy. Dysplasia is the best histologic marker for cancer risk.

The management options for high-grade dysplasia include the following:

  • Surveillance endoscopy, with intensive biopsy at 3-month intervals until cancer is detected
  • Endoscopic ablation: In most major medical centers, ablation is first-line therapy
  • Surgical resection: While studies have shown surgery to be efficacious in the control of GERD symptoms, no good evidence indicates that surgical therapy provides regression in Barrett esophagus

Pharmacologic treatment for Barrett esophagus should be the same as that for GERD, although most authorities agree that treatment should employ a proton pump inhibitor (PPI) instead of an H2-receptor antagonist, due to the relative acid insensitivity of patients with Barrett esophagus. While PPIs have been found to be better than H2-receptor antagonists at reducing gastric acid secretion, the evidence as to whether PPIs induce regression of Barrett esophagus remains inconclusive.

Diet

The diet for patients with Barrett esophagus is the same as that recommended for patients with GERD. Patients should avoid the following:

  • Fried or fatty foods
  • Chocolate
  • Peppermint
  • Alcohol
  • Coffee
  • Carbonated beverages
  • Citrus fruits or juices
  • Tomato sauce
  • Ketchup
  • Mustard
  • Vinegar
  • Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs)

See Treatment and Medication for more detail.

Next

Background

Barrett esophagus is well recognized as a complication of gastroesophageal reflux disease (GERD). Prolonged exposure of the esophagus to the refluxate of GERD can erode the esophageal mucosa, promote inflammatory cell infiltrate, and ultimately cause epithelial necrosis. This chronic damage is believed to promote the replacement of healthy esophageal epithelium with the metaplastic columnar cells of Barrett esophagus. Why only some people with GERD develop Barrett esophagus is not clear (see the image below).

Barrett esophagus (BE). The salmon-pink area has s Barrett esophagus (BE). The salmon-pink area has specialized intestinal metaplasia. The white area is squamous epithelium.

Histologic characteristics

The definition of Barrett esophagus (BE) has evolved considerably over the past 100 years. In 1906, Tileston, a pathologist, described several patients with "peptic ulcer of the oesophagus" in which the epithelium around the ulcer closely resembled that normally found in the stomach. The debate for the next 4 decades centered on the anatomic origin of this mucosal anomaly. Many investigators, including Barrett in his treatise published in 1950, supported the view that this ulcerated, columnar-lined organ was, in fact, the stomach tethered within the chest by a congenitally short esophagus.[1]

In 1953, Allison and Johnstone argued that the columnar organ was more likely esophagus, because the intrathoracic region lacked a peritoneal covering, contained submucosal glands and muscularis propria characteristic of the esophagus, and could harbor islands of squamous cells within the columnar segment.[2] In 1957, Barrett agreed and suggested that the condition that bears his name be referred to as "lower esophagus lined by columnar epithelium."[3] For the next 2 decades, descriptions of the histology of Barrett esophagus varied considerably from acid-secreting, fundic-type epithelium to intestinal-type epithelium with goblet cells.

Finally, in 1976, Paull et al published a report on the histologic spectrum of Barrett esophagus in which they used manometric guidance for their biopsies.[4] The study’s patients had 1 or a combination of 3 types of columnar epithelium; ie, a gastric fundic-type, a junctional type, and a distinctive type of intestinal metaplasia the investigators called "specialized columnar epithelium." This specialized intestinal metaplasia (SIM), complete with goblet cells, has become the sine qua non for the diagnosis of Barrett esophagus.

Endoscopic characteristics

However, while Paull et al’s study clarified the nature of the histologic lesion, the endoscopic definition of Barrett esophagus has continued to change. Many people believed that the distal esophagus could contain a normal region of columnar mucosa. In addition, determining the exact location of the esophagogastric junction (EGJ) in patients with Barrett esophagus often is difficult. To avoid false-positive diagnoses, investigators selected arbitrary lengths of columnar-lined esophagus to establish a diagnosis for their studies. Eventually, community endoscopists embraced this practice, and biopsy of the so-called normal distal columnar-lined esophagus was avoided.

Convincing evidence indicates that SIM, the hallmark histologic lesion of Barrett esophagus, predisposes to dysplasia and cancer regardless of the endoscopic location. Thus, the definition of Barrett esophagus currently is the finding of SIM anywhere within the tubular esophagus.

Previous
Next

Etiology

As previously stated, Barrett esophagus is well recognized as a complication of GERD. Patients with GERD who develop Barrett esophagus tend to have a combination of clinical features, including hiatal hernia, reduced lower esophageal sphincter (LES) pressures, delayed esophageal acid clearance time, and duodenogastric reflux (as documented by the presence of bile in the esophageal lumen).

Increasing trends for obesity and its associations with GERD and Barrett esophagus are risk factors for esophageal adenocarcinoma.[5] Abdominal obesity is in itself independently increases the risk of Barret esophagus.[5]

Pathogenesis of GERD

An understanding of the pathogenesis of GERD is necessary to understand the relationship between GERD and Barrett esophagus. Esophageal defense mechanisms against the noxious substances in the refluxate include an antireflux barrier, an efficient clearing mechanism, and epithelial defense factors.

The antireflux barrier is a high-pressure zone at the EGJ that is generated by tonic contraction of the LES coupled with extrinsic compression by the right crus of the diaphragm. The phrenoesophageal ligament, intra-abdominal location of the LES, and maintenance of an acute angle of entry into the stomach help to reinforce this barrier.

This system is imperfect due to the existence of physiologic transient LES relaxations (TLESRs). TLESRs occur primarily after meals but in the absence of a preceding swallow. Studies indicate that about 95% of reflux episodes in healthy controls occur during the TLESR. Most reflux in patients with GERD occurs via this same mechanism. The duration of esophageal acidification, and not the frequency, correlates best with presence of erosive esophagitis.

A healthy individual clears the esophagus through various means, including gravity, bicarbonate secretion from the salivary and esophageal glands, and peristalsis. Dysfunctional esophageal motility with failed or weak peristalsis is a contributing factor in 34-48% of patients with GERD.

An acid (pH < 4) contact time of 1-2 hours per day is considered normal in the distal esophagus. This physiologic reflux occurs in completely asymptomatic individuals. The esophagus, therefore, must have additional local means of protection.

The esophagus is composed of a thick epithelial layer, with cells joined by tight junctions with lipid-rich intercellular spaces. This arrangement resists the diffusion of noxious substances by limiting entry of H+ into cells and intercellular spaces. In addition, scattered submucosal glands in the distal esophagus that secrete bicarbonate and have an adequate blood supply to deliver bicarbonate and remove H+ help to maintain tissue acid-base balance.

The aggressors in the GERD battle reside in the refluxate. Mucosal injury depends on the pH of the refluxate and the duration of contact with the esophageal mucosa. Lower pH of the refluxate and extended contact with the esophagus increases the time required for intraesophageal pH to return to normal and increases the risk for mucosal injury.

Refluxate exposure and Barrett esophagus

Prolonged exposure of the esophagus to the refluxate can erode the esophageal mucosa, promote inflammatory cell infiltrate, and ultimately cause epithelial necrosis. This chronic damage is believed to promote the replacement of healthy esophageal epithelium with the metaplastic columnar cells of Barrett esophagus, the cellular origin of which remains unknown. This likely is an adaptive response of the esophagus, which, if not for the increased risk of cancer, would have been beneficial. GERD symptoms and strictures are less common in the columnarized segment.

Interestingly, the features of GERD in relation to long-segment Barrett esophagus (LSBE >3 cm) and short-segment Barrett esophagus (SSBE < 3 cm) are quite different. Patients with LSBE tend to have a longer duration of reflux symptoms, and, when undergoing 24-hour esophageal pH monitoring, they have severe, combined patterns of reflux (both supine and erect) and low LES pressures. They also tend to be less sensitive to direct acid exposure. On the other hand, patients with SSBE are more sensitive to acid exposure but have had symptoms for a shorter duration, with normal LES pressures and only upright reflux on 24-hour esophageal pH testing.

Current clinical practice guidelines recommend screening for Barrett esophagus in patients with GERD when the patients have had long-standing symptoms (>5 y); this is especially recommended in patients older than 50 years.

Oral bisphosphonate use and Barrett esophagus

Use of oral bisphosphonates was associated with an increased risk of Barrett esophagus, especially among patients with GERD, in a case-control analysis of US veterans, including 285 with definitive Barrett esophagus, 1,122 endoscopy controls, and 496 primary care controls.[6, 7] Overall, 54 (2.8%) of the study participants had filled prescriptions for oral bisphosphonates.

More patients with Barrett esophagus (4.6%) than controls combined (2.5%) had filled prescriptions for any oral bisphosphonate, and significantly more patients with Barrett esophagus (4.2%) than controls (2.2%) had alendronate prescriptions.[6, 7] In a model adjusted for age, sex, race, proton-pump (PPI) inhibitor use, hiatal hernia, H pylori infection, and GERD symptoms, oral bisphosphonates were associated with a significant 2.33-fold increase in the risk of Barrett esophagus. This association increased to 3.29-fold when analyses were limited to patients with GERD symptoms, but there was no association among patients without GERD symptoms.[6, 7] Similarly, the risk was increased 2.71-fold among PPI users, but it was not significantly increased in patients without PPI use.

Previous
Next

Epidemiology

The average age of patients with Barrett esophagus is 55-65 years. The condition occurs in a 2:1 male-to-female ratio, with white males making up more than 80% of cases. Some studies indicate a higher prevalence of smoking, alcohol intake, and obesity in persons with the disease.[5]

Estimates of the prevalence of Barrett esophagus vary considerably and range from 0.9-10% of the general adult population. A study from Sweden by Ronkainen and colleagues estimated the prevalence to be approximately 2% in the adult population.[8] This particular study is believed to be one of the more reliable because of the means by which the epidemiologic data could be assessed in Sweden. In US population terms, this prevalence would equate to approximately 3 million adults with Barrett esophagus.

The prevalence of LSBE in patients undergoing endoscopy for any clinical indication has been reported at 0.3-2% but is much higher, 8-20%, in patients with symptoms of GERD. A study conducted at the Mayo Clinic showed an autopsy prevalence about 17 times higher than a clinically matched population, suggesting that most cases of LSBE are asymptomatic and thus unrecognized. In patients undergoing endoscopy, the prevalence of SSBE ranges from 5-30%. The combined prevalence of SSBE and cardia-SIM is 7-8 times greater than LSBE, but the prevalence of dysplasia and cancer is much less.

In a study of 120 young patients (range, 16-19 years; mean age, 16.5 ± 1.4 years) treated for esophageal atresia, Barrett esophagus was associated with eosophageal atresia without fistula, previous multiple antireflux surgery, esophageal dilation, suspicion of BE at endoscopy , and histologic esophagitis.[9]

Previous
Next

Prognosis

The most significant morbidity associated with Barrett esophagus is the development of adenocarcinoma in the esophagus.[5] However, most patients with Barrett esophagus will not develop esophageal cancer, with the risk of progression to adenocarcinoma of the esophagus being estimated at approximately 0.5% per year in patients without dysplasia on initial surveillance biopsies.

Even so, the incidence of esophageal adenocarcinoma is rising faster than that of any other cancer in the United States. From 1926-1976, 4 large surgical series reported that only 0.8-3.7% of esophageal cancers were adenocarcinomas. From 1979-1992, this increased to 54-68%.

Blot et al, in a review of data from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, determined that the incidence of esophageal adenocarcinoma in 1988-1990 was 3 times that in 1976-1978.[10]

In Olmstead County, Minnesota, Pera et al conducted a population-based study and found that the incidence of esophageal adenocarcinoma rose from 0.13 cases per 100,000 person-years in 1935-1971 to 0.74 cases per 100,000 person-years in 1974-1989.[11] The incidence of adenocarcinoma of the cardia rose from 0.25 to 1.34 cases per 100,000 person-years in the same time period, an increase of more than 5-fold for both locations. Patients with LSBE have the greatest risk for development of dysplasia and adenocarcinoma of the esophagus.

Studies report the prevalence of dysplasia in LSBE at 20-35%, in SSBE at 6-8%, and in cardia-SIM at 0-6%, with the prevalence of adenocarcinoma being 7-15 times greater in LSBE than in SSBE and cardia-SIM. However, the total number of patients with SSBE and cardia-SIM is 7-8 times that of LSBE. Thus, even with a higher prevalence of dysplasia and cancer in the LSBE population, a greater total number of patients are likely to develop cancer from within the SSBE and EGJ-SIM group.

Previous
 
 
Contributor Information and Disclosures
Author

Mark H Johnston, MD Associate Professor of Medicine, Uniformed Services University of the Health Sciences; Consulting Staff, Lancaster Gastroenterology, Inc

Mark H Johnston, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, Christian Medical and Dental Associations

Disclosure: Nothing to disclose.

Coauthor(s)

John A Eastone, MD 

John A Eastone, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians-American Society of Internal Medicine, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Specialty Editor Board

Marco G Patti, MD Professor of Surgery, Director, Center for Esophageal Diseases, University of Chicago Pritzker School of Medicine

Marco G Patti, MD is a member of the following medical societies: American Association for the Advancement of Science, American Surgical Association, American College of Surgeons, American Gastroenterological Association, American Medical Association, Association for Academic Surgery, Pan-Pacific Surgical Association, Society for Surgery of the Alimentary Tract, Society of American Gastrointestinal and Endoscopic Surgeons, Southwestern Surgical Congress, Western Surgical Association

Disclosure: Nothing to disclose.

Chief Editor

Praveen K Roy, MD, AGAF Chief of Gastroenterology, Presbyterian Hospital; Medical Director of Endoscopy, Presbyterian Medical Group; Adjunct Associate Research Scientist, Lovelace Respiratory Research Institute

Praveen K Roy, MD, AGAF is a member of the following medical societies: American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Acknowledgements

John A Eastone, MD Gastroenterology Fellow, Bethesda and Walter Reed Army Medical Center; Instructor, Department of Internal Medicine, F Edward Herbert School of Medicine, Uniformed Services University of the Health Sciences

John A Eastone, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians-American Society of Internal Medicine, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Ronnie Fass, MD Chief of Gastroenterology, Southern Arizona VA Health Care System; Professor of Medicine, Division of Gastroenterology, University of Arizona School of Medicine

Ronnie Fass, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians-American Society of Internal Medicine, American Gastroenterological Association, American Motility Society, American Society for Gastrointestinal Endoscopy, and Israel Medical Association

Disclosure: Takeda Pharmaceuticals Grant/research funds Conducting research; Takeda Pharmaceuticals Consulting fee Consulting; Takeda Pharmaceuticals Honoraria Speaking and teaching; Vecta Consulting fee Consulting; XenoPort Consulting fee Consulting; Eisai Honoraria Speaking and teaching; Wyeth Pharmaceuticals Conducting research; AstraZeneca Grant/research funds Conducting research; Eisai Consulting fee Consulting

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References
  1. Barrett NR. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg. 1950 Oct. 38(150):175-82. [Medline].

  2. Allison PR, Johnstone AS. The oesophagus lined with gastric mucous membrane. Thorax. 1953 Jun. 8(2):87-101. [Medline].

  3. Barrett NR. The lower esophagus lined by columnar epithelium. Surgery. 1957 Jun. 41(6):881-94. [Medline].

  4. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett's esophagus. N Engl J Med. 1976 Aug 26. 295(9):476-80. [Medline].

  5. Thrift AP. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Gastroenterol. 2016 Jul. 32 (4):319-24. [Medline].

  6. Lin D, Kramer JR, Ramsey D, Alsarraj A, Verstovsek G, Rugge M, et al. Oral Bisphosphonates and the Risk of Barrett's Esophagus: Case-Control Analysis of US Veterans. Am J Gastroenterol. 2013 Jul 16. [Medline].

  7. Boggs W. Oral Bisphosphonates Linked to Higher Risk of Barrett's Esophagus. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/809310. Accessed: August 20, 2013.

  8. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005 Dec. 129(6):1825-31. [Medline].

  9. Schneider A, Gottrand F, Bellaiche M, et al. Prevalence of Barrett esophagus in adolescents and young adults with esophageal atresia. Ann Surg. 2015 Dec 28. [Medline].

  10. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991 Mar 13. 265(10):1287-9. [Medline].

  11. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993 Feb. 104(2):510-3. [Medline].

  12. Allan EA, Miller R, Going JJ. Aneusomy detected by fluorescence in-situ hybridization has high positive predictive value for Barrett's dysplasia. Histopathology. 2015 Oct. 67 (4):451-6. [Medline].

  13. Haag S, Nandurkar S, Talley NJ. Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods. Gastrointest Endosc. 1999 Aug. 50(2):229-40. [Medline].

  14. Rayner CJ, Gatenby P. Effect of antireflux surgery for Barrett's esophagus: long-term results. Minerva Chir. 2016 Jun. 71 (3):180-91. [Medline].

  15. Krishnamoorthi R, Singh S, Ragunathan K, A Katzka D, K Wang K, G Iyer P. Risk of recurrence of Barrett's esophagus after successful endoscopic therapy. Gastrointest Endosc. 2016 Jun. 83 (6):1090-1106.e3. [Medline].

  16. Zhao Z, Pu Z, Yin Z, et al. Dietary fruit, vegetable, fat, and red and processed meat intakes and Barrett's esophagus risk: a systematic review and meta-analysis. Sci Rep. 2016 Jun 3. 6:27334. [Medline].

  17. Prasad GA, Wang KK, Buttar NS, Wongkeesong LM, Krishnadath KK, Nichols FC 3rd, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2007 Apr. 132(4):1226-33. [Medline].

  18. Brown T. Barrett's Esophagus: Endoluminal Therapy Safe, Effective. Medscape Medical News. February 15, 2013. Available at http://www.medscape.com/viewarticle/779427. Accessed: March 11, 2013.

  19. Guarner-Argente C, Buoncristiano T, Furth EE, Falk GW, Ginsberg GG. Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc. 2013 Feb. 77(2):190-9. [Medline].

  20. Nayna L, Emma W, Vani K. Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus. Curr Opin Gastroenterol. 2016 Jul. 32 (4):294-301. [Medline].

  21. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009 May 28. 360(22):2277-88. [Medline]. [Full Text].

  22. Brooks M. Ablation beats surveillance for Barrett esophagus and low-grade dysplasia. Medscape Medical News. March 27, 2014. [Full Text].

  23. Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014 Mar 26. 311(12):1209-17. [Medline].

  24. Mönkemüller K. Radiofrequency ablation for Barrett esophagus with confirmed low-grade dysplasia. JAMA. 2014 Mar 26. 311(12):1205-6. [Medline].

  25. Agoston AT, Strauss AC, Dulai PS, et al. Predictors of treatment failure after radiofrequency ablation for intramucosal adenocarcinoma in Barrett esophagus: a multi-institutional retrospective cohort study. Am J Surg Pathol. 2015 Dec 5. [Medline].

  26. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999 Jan. 49(1):1-7. [Medline].

  27. Sampliner RE, Fennerty B, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc. 1996 Nov. 44(5):532-5. [Medline].

  28. Allison H, Banchs MA, Bonis PA, Guelrud M. Long-term remission of nondysplastic Barrett's esophagus after multipolar electrocoagulation ablation: report of 139 patients with 10 years of follow-up. Gastrointest Endosc. 2011 Apr. 73(4):651-8. [Medline].

  29. Boggs W. PPIs may reduce esophageal cancer risk in Barrett's esophagus. Reuters Health Information. November 26, 2013. [Full Text].

  30. Bremner RM, Mason RJ, Bremner CG, DeMeester TR, Chandrasoma P, Peters JH, et al. Ultrasonic epithelial ablation of the lower esophagus without stricture formation. A new technique for Barrett's ablation. Surg Endosc. 1998 Apr. 12(4):342-6; discussion 346-7. [Medline].

  31. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am. 1997 Sep. 26(3):487-94. [Medline].

  32. Dodds WJ, Dent J, Hogan WJ, Helm JF, Hauser R, Patel GK, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med. 1982 Dec 16. 307(25):1547-52. [Medline].

  33. Johnston CM, Schoenfeld LP, Mysore JV, Dubois A. Endoscopic spray cryotherapy: a new technique for mucosal ablation in the esophagus. Gastrointest Endosc. 1999 Jul. 50(1):86-92. [Medline].

  34. Kahrilas PJ, Dodds WJ, Hogan WJ, Kern M, Arndorfer RC, Reece A. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology. 1986 Oct. 91(4):897-904. [Medline].

  35. Pereira-Lima JC, Busnello JV, Saul C, Toneloto EB, Lopes CV, Rynkowski CB, et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol. 2000 Jul. 95(7):1661-8. [Medline].

  36. Sampliner RE. Ablative therapies for the columnar-lined esophagus. Gastroenterol Clin North Am. 1997 Sep. 26(3):685-94. [Medline].

  37. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1998 Jul. 93(7):1028-32. [Medline].

  38. Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2013 Nov 12. [Medline].

  39. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996 Feb. 110(2):614-21. [Medline].

  40. Ter RB, Castell DO. Gastroesophageal reflux disease in patients with columnar-lined esophagus. Gastroenterol Clin North Am. 1997 Sep. 26(3):549-63. [Medline].

  41. Wong RKH. Barrett's esophagus. Pract Gastroenterol. 2000. 24:15-35.

  42. Hagen CE, Lauwers GY, Mino-Kenudson M. Barrett esophagus: diagnostic challenges. Semin Diagn Pathol. 2014 Mar. 31 (2):100-13. [Medline].

  43. Dunbar KB, Spechler SJ. Controversies in Barrett esophagus. Mayo Clin Proc. 2014 Jul. 89 (7):973-84. [Medline].

  44. Jankowski J, Bennett C, Jankowski JA. Management of Barrett esophagus: a practical guide for clinicians based on the BADCAT and BoB CAT recommendations. Pol Arch Med Wewn. 2015 Oct 28. 125 (10):765-70. [Medline].

  45. Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016 Jun 21. [Medline].

 
Previous
Next
 
Barrett esophagus (BE). The salmon-pink area has specialized intestinal metaplasia. The white area is squamous epithelium.
Cryoablation of esophageal lining in Barrett esophagus (BE). This is one of the newest experimental ablative therapies for the esophagus performed at the author's laboratory.
Blistering of the esophageal mucosal layer after cryoablation in Barrett esophagus (BE).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.